At Verily, a growing line of business builds on a revolving door to the FDA

2022-10-09 07:13:27 By : Ms. Shelly Cui

Exclusive analysis of biotech, pharma, and the life sciences

In-depth analysis of biotech, pharma, and the life sciences

from some of the nation's most trusted and well-connected reporters in the industry

with STAT+ reporters and leading industry experts in our STAT+ Conversations series

hosted by STAT+, plus early-bird access and discounts to industry events around the country

get delivered to your inbox to brief you on the most important industry news of the day

like our CRISPR Trackr and Drug Pricing Policy Tracker

In-depth analysis of biotech, pharma, and the life sciences

from some of the nation's most trusted and well-connected reporters in the industry

with STAT+ reporters and leading industry experts in our STAT+ Conversations series

hosted by STAT+, plus early-bird access and discounts to industry events around the country

get delivered to your inbox to brief you on the most important industry news of the day

like our CRISPR Trackr and Drug Pricing Policy Tracker

After years spent building a seemingly slapdash set of medical initiatives, Verily seems to have a game plan.

The Alphabet life sciences spinout is doubling down on the business of evidence generation , trying to build the tools and technical infrastructure that will help pharma and digital health customers run the next generation of clinical trials. It’s an area that Verily and its investors — who just poured $1 billion into the company — are predicting can become a lucrative line of business. And Verily is backing up that bet by filling its ranks with some of the Food and Drug Administration’s top scientific, policy, and legal experts. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Katie is a health tech correspondent at STAT.

This name will appear with your comment

There was an error saving your display name. Please check and try again.

Reporting from the frontiers of health and medicine

You've been selected! Subscribe to STAT+ for less than $2 per day

Unlimited access to essential biotech, medicine, and life sciences journalism

Subscribe to STAT+ for less than $2 per day

Unlimited access to the health care news and insights you need